BIOТЕСН
Fast Company|Summer 2023
Moderna's Next Shot Two and a half years after its COVID-19 vaccine hit, the pandemic darling is still trying to conjure a follow-up act.
ADAM BLUESTEIN
BIOТЕСН

"SCIENCE DOESN'T move in a straight line," says Stéphane Bancel, "especially with cutting-edge science that no human has done before you." The 50-year-old CEO of the biotech company Moderna is familiar with circuitous journeys and unexpected turns of fate.

Founded in 2010 by a group of influential scientists from Harvard and MIT, Moderna spent its first decade pursuing research into the then-novel idea of using mRNA as a platform to create vaccines and drugs that essentially manufacture themselves in a patient's body. But by early 2020, it still didn't have a single product on the market. It did, however, have six vaccines in Phase 1 trials, and was working on one against MERS, a type of coronavirus. And it had built a 150,000-square-foot facility in the Boston suburb of Norwood, ready to mass-produce mRNA vaccines. Just in case.

When the genetic sequence of a novel coronavirus from China was made public on January 11, 2020, Moderna was ready. It tapped its mRNA platform to develop a new vaccine candidate, and on December 18, 2020, it obtained FDA emergency use authorization (EUA) for a COVID-19 vaccine, marking one of the shortest vaccine-development cycles ever. (The FDA issued an EUA for the Pfizer-BioNTech COVID-19 vaccine just one week earlier.) The company produced billions of doses over the next couple of years, driving annual revenue from $60 million in 2019 to $18.4 billion last year.

But as demand for COVID-19 booster shots wanes-and with a flurry of competitors now developing their own mRNA vaccines and drugs-Moderna finds itself once again seeking its way. For investors, who sent the company's market cap skyrocketing from roughly $6 billion in 2019 to $196 billion at its peak in August 2021 (it's now back at a more earthbound $50 billion), the company needs to prove that it's not a one-shot wonder, or even "just" a vaccine maker.

Diese Geschichte stammt aus der Summer 2023-Ausgabe von Fast Company.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der Summer 2023-Ausgabe von Fast Company.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS FAST COMPANYAlle anzeigen
Where the Clean Energy Jobs Are
Fast Company

Where the Clean Energy Jobs Are

A data-driven guide to the skills you need and the opportunities you'll find

time-read
5 Minuten  |
Winter 2024 - 2025
CAN WWE PIN THE WORLD?
Fast Company

CAN WWE PIN THE WORLD?

AS IT MAKES ITS $5 BILLION NETFLIX DEBUT AND PREPARES FOR A GLOBAL AUDIENCE, WWE IS STILL WRESTLING WITH THE TOXIC LEGACY OF ITS COMPLICATED FOUNDER.

time-read
10 Minuten  |
Winter 2024 - 2025
RADICAL VISION
Fast Company

RADICAL VISION

POLICE DEPARTMENTS ACROSS THE COUNTRY ARE EMBRACING AI-ENHANCED SURVEILLANCE IN THE NAME OF STOPPING CRIME. HERE'S HOW ONE SECURITY FIRM IS LEADING THE EFFORT AND PROFITING OFF OUR FEARS

time-read
10+ Minuten  |
Winter 2024 - 2025
Brands That Matter
Fast Company

Brands That Matter

Our annual look at standout brands encompasses 130 honorees in nine categories, including the inaugural CMOs of the Year. Here's how 12 of those brands and three top CMOs stake out the intersection of business and culture.

time-read
10+ Minuten  |
Winter 2024 - 2025
The Future According to Google
Fast Company

The Future According to Google

Google DeepMind, the tech giant's internal AI research lab, isn't just racing to beat OpenAI to market. Under Nobel laureate CEO Demis Hassabis, it's the \"engine room\" of the entire company.

time-read
10+ Minuten  |
Winter 2024 - 2025
EYE OF THE BEHOLDER
Fast Company

EYE OF THE BEHOLDER

SEPHORA HAS GROWN SO POWERFUL THAT IT CONTROLS WHICH BRANDS LIVE OR DIE IN THE $30 BILLION HIGH-END COSMETICS INDUSTRY. IN THIS BEAUTY CONTEST, SEPHORA ALWAYS WEARS THE CROWN.

time-read
10+ Minuten  |
Winter 2024 - 2025
CULTURE WARS
Fast Company

CULTURE WARS

Brands on the Run Why Harley-Davidson, Caterpillar, and other masculine\" brands are caving to anti-DEI crusader Robby Starbuck

time-read
6 Minuten  |
Winter 2024 - 2025
WORK LIFE
Fast Company

WORK LIFE

Law Roach, image architect and educator, answers our career questionnaire.

time-read
2 Minuten  |
Winter 2024 - 2025
The AI Gadget Debacle
Fast Company

The AI Gadget Debacle

Here's why you shouldn't expect any mind-blowing AI-powered gifts anytime soon.

time-read
6 Minuten  |
Winter 2024 - 2025
Why the future workplace will feel more like a hotel
Fast Company

Why the future workplace will feel more like a hotel

REVEALS WHY THIS IS IMPORTANT TO CORPORATE STRATEGY AND EMPLOYEE ENGAGEMENT

time-read
2 Minuten  |
Winter 2024 - 2025